Mutant KRAS in cancer cells stimulates cytokine receptor expression such as such as IL4R, IL2Rγ, and IL13Rα1 that, in turn, facilitate the Jak1-Stat6-cMyc pathway activation by IL-4 and IL-13. Here, KRAS is linked to cancer.